Susan writes:
Hi Dr. Griffin –
Have you seen an increase in NTM, MAC, and Bronchectiasis since COVID-19? I am a 65-year-old female who has had all of my vaccinations and COVID-19 twice. I have also had another respiratory virus that wasn’t identified. I have recently been diagnosed with NTM, Mac, and Bronchectiasis.
Thank you for all the information you provide each week to keep us informed.
Susan
Charles writes:
Hello Doctors;
I saw this today and it fit with my previous two emails, so I am sending the link:
https://www.medpagetoday.com/special-reports/features/112871
I really would like to understand why the IDSA Guidelines on the Treatment and Management of Patients with COVID-19 has the following:
Nirmatrelvir/Ritonavir: Conditional recommendation†, Low certainty of evidence
Remdesivir: Conditional recommendation†, Low certainty of evidence
or: Conditional recommendation†, Moderate certainty of evidence
depending on conditions with the patient.
Molnupiravir: Conditional recommendation†, Low certainty of evidence
Convalescent Plasma immunocompromised patients:
Conditional recommendation, very low certainty of evidence:
†The guideline panel concluded that the desirable effects outweigh the undesirable effects, though uncertainty still exists, and most informed people would choose the suggested course of action, while a substantial number would not.
I am a computer programmer, not an MD. When I look at the evidence for the first 3, I do not see a low certainty of evidence. In the large well run (ie, treatment given early) studies, I see a high certainty of evidence. What do I have wrong or why is the IDSA being so conservative?
Thanks,
Charles
Lis writes:
Could Daniel add the required reporting data that starts Nov 1 to Clinical Updates. (See below)Thanks for all you do.
Lis
- On April 30, 2024, some federal reporting requirements for hospitals and critical access hospitals expired as specified in the regulations at that time. This resulted in voluntary data reporting, which led to reduced visibility.
- The Centers for Medicare & Medicaid Services (CMS) has issued a new rule
- requiring hospitals and critical access hospitals (CAHs) to report information about COVID-19, influenza, and RSV starting November 1, 2024.
- Source https://www.cdc.gov/ncird/whats-new/updated-hospital-reporting-requirements-for-respiratory-viruses.html
Mike writes:
Hi Daniel,
Given the MNRA vaccines don’t seem so durable, is there a possibility the J&J actually wasn’t as ineffective as people thought if it had been compared over a longer time period? Are there any studies on this?
Mike (who got a J&J vaccine and had all his friends make fun of him)
Hat writes:
Quick Question:
Should we be treating Asymptomatic Congenital Hepatitis B Patients with Etecavir/Tenofovir to delay onset of liver disease a/o cancer?
Thanks
Connie writes:
Daniel and Vincent,
Thank you for your invaluable show, which has gotten me through Covid !
Do you have any information on what steps the government or industry are taking in developing a vaccine for the avian flu ? It doesn’t seem far-fetched that the virus will mutate to be dangerous to humans. Could the mortality rate really be 50 % ?
Thanks,
Connie